Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bluejeans who wrote (18795)	4/7/1998 1:08:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Bob, I haven't heard anything, but since I didn't see a press release, I would assume that the data presented is similar to the press release that came out last month on Panretin oral treatment of KS.

To: bluejeans who wrote (18795)	4/7/1998 2:54:00 PM
From: Henry Niman	Respond to of 32384

Although the press release didn't have much news, it was covered by Dow Jones as well as PRNewswire: Dow Jones Newswires -- April 7, 1998 Ligand: Panretin Capsules Effective Against Kaposi's Sarcoma SAN DIEGO (Dow Jones)--Ligand Pharmaceuticals Inc.'s (LGND) Panretin capsules demonstrated "substantial" antitumor activity in patients with AIDS-related Kaposi's sarcoma, according to data from Phase II clinical trials. In a press release Tuesday, Ligand said if Phase III data support the results, it may file a new drug application in 1999. In the Phase II multicenter, open-label clinical trial, Panretin capsules were given to 57 male HIV-positive patients with Kaposi's sarcoma. The company said 26 of the patients, in the intent-to-treat dataset, received the study drug and had at least one set of lesion assessments at the interim phase of the trial. The company said the overall response rate at the interim analysis was 46% for the intent-to-treat dataset, and 63% for the protocol-defined evaluable patient dataset. The Panretin capsules study was separate from Ligand's Phase III pivotal trial for Panretin gel, another treatment for AIDS-related Kaposi's sarcoma.